Model for end-stage liver disease (MELD) exception for uncommon hepatic tumors.

Liver transplantation has been performed for a wide variety of rare hepatic tumors. The anecdotal nature of this experience makes evidence-based decisions regarding suitability for transplantation very challenging. The largest reports of transplantation for tumors other than hepatocellular carcinoma and cholangiocarcinoma have been for neuroendocrine tumors. Hepatic metastases are present in approximately 75% of patients at the time a neuroendocrine tumor is diagnosed, and cure by liver transplantation (LT) is rare.